303 related articles for article (PubMed ID: 19364951)
1. Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis.
Koo YX; Tan DS; Tan BH; Quek R; Tao M; Lim ST
J Clin Oncol; 2009 May; 27(15):2570-1; author reply 2571-2. PubMed ID: 19364951
[No Abstract] [Full Text] [Related]
2. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
3. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
4. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
5. Surveillance and treatment protocols to detect and treat hepatitis B virus reactivation in hepatitis B surface antigen-negative/antibody to hepatitis B core antigen-positive patients receiving chemotherapy for onco-hematologic malignancies.
Marignani M; Marzano A
J Clin Oncol; 2011 Mar; 29(8):e210; author reply e211. PubMed ID: 21220585
[No Abstract] [Full Text] [Related]
6. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
7. Combined lamivudine and interferon-alpha therapy for chemotherapy-induced reactivation of hepatitis B virus.
Ohmoto K; Tsuduki M; Yamamoto S
Am J Gastroenterol; 2003 May; 98(5):1215-6; author reply 1217. PubMed ID: 12809863
[No Abstract] [Full Text] [Related]
8. Entecavir as prophylaxis against hepatitis B virus reactivation following chemotherapy for lymphoma.
Uchiyama M; Tamai Y; Ikeda T
Int J Infect Dis; 2010 Mar; 14(3):e265-6. PubMed ID: 19665406
[No Abstract] [Full Text] [Related]
9. Fatal reactivation of hepatitis B after chemotherapy for lymphoma.
Dillon R; Hirschfield GM; Allison ME; Rege KP
BMJ; 2008 Jul; 337():a423. PubMed ID: 18595895
[No Abstract] [Full Text] [Related]
10. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
Leaw SJ; Yen CJ; Huang WT; Chen TY; Su WC; Tsao CJ
Ann Hematol; 2004 May; 83(5):270-5. PubMed ID: 15060745
[TBL] [Abstract][Full Text] [Related]
11. [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
Muñoz Bertrán E; Pérez Ceballos E; Gómez Espín R; Ortega González I
Gastroenterol Hepatol; 2010 May; 33(5):377-81. PubMed ID: 20363054
[TBL] [Abstract][Full Text] [Related]
12. Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab.
Stange MA; Tutarel O; Pischke S; Schneider A; Strassburg CP; Becker T; Barg-Hock H; Bastürk M; Wursthorn K; Cornberg M; Ott M; Greten TF; Manns MP; Wedemeyer H
Z Gastroenterol; 2010 Feb; 48(2):258-63. PubMed ID: 20127601
[TBL] [Abstract][Full Text] [Related]
13. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations.
Law JK; Ho JK; Hoskins PJ; Erb SR; Steinbrecher UP; Yoshida EM
Leuk Lymphoma; 2005 Jul; 46(7):1085-9. PubMed ID: 16019563
[TBL] [Abstract][Full Text] [Related]
14. Severe reactivation of hepatitis B virus infection in a patient with hairy cell leukemia: Should lamivudine prophylaxis be recommended to HBsAg-negative, anti-HBc-positive patients?
Orlando R; Tosone G; Tiseo D; Piazza M; Portella G; Ciancia R; Martinelli V; Montante B; Rotoli B
Infection; 2006 Oct; 34(5):282-4. PubMed ID: 17033754
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.
Lubel JS; Angus PW
J Gastroenterol Hepatol; 2010 May; 25(5):864-71. PubMed ID: 20546439
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis.
Zurawska U; Hicks LK; Woo G; Bell CM; Krahn M; Chan KK; Feld JJ
J Clin Oncol; 2012 Sep; 30(26):3167-73. PubMed ID: 22711851
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis against hepatitis B reactivation among patients with lymphoma receiving rituximab.
Buensalido JA; Chandrasekar PH
Expert Rev Anti Infect Ther; 2014 Feb; 12(2):151-4. PubMed ID: 24341369
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of hepatitis B virus in patients receiving chemotherapy.
Ikeda M
Jpn J Clin Oncol; 2013 Jan; 43(1):8-16. PubMed ID: 23183929
[TBL] [Abstract][Full Text] [Related]
19. [Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab].
Mimura N; Kojima H; Tsujimura H; Ise M; Sakai C; Fukai K; Yokosuka O; Kumagai K
Rinsho Ketsueki; 2010 Mar; 51(3):213-5. PubMed ID: 20379117
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B surface antigen seroreversion in a T-cell lymphoma patient.
Chen HW; Lin SA; Lin HC; Kao WY
J BUON; 2011; 16(2):374-6. PubMed ID: 21766517
[No Abstract] [Full Text] [Related]
[Next] [New Search]
